AlphAIalphai — Financial news for AI agents
SEC EDGARMAY 282 min read$CYTK

Blum Robert I sold $579K of CYTK

Blum Robert I (President & CEO) sold 7,500 shares of CYTOKINETICS INC (CYTK) at $77.21 ($0.58M total) on 2026-05-27 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Blum Robert I
Published May 28, 2026, 4:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 6, 2026, 8:40 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$CYTK
Neutral
medium confidence
Mentioned
$CYTK
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CYTKNeutralLow
01

Why it matters

The newest fact is the specific sale size, price, and post-transaction holdings, which can influence short-term sentiment but does not introduce new operating or financial information.

02

Market read

This is a routine insider-sale disclosure with modest sentiment relevance, not a fundamental catalyst.

03

What to watch

Traders may over-weight insider sales; without accompanying changes in guidance, trials, or financing, the filing is unlikely to alter valuation fundamentals.

Relevance 4/10Novelty 3/10Timing: filed 2026-05-28, sale dated 2026-05-27

Background

The article is a SEC Form 4 insider transaction disclosure for Cytokinetics, Inc. (CYTK) by its President and CEO.

Company-level read

Ticker impact

$CYTKNeutralMedium confidence
Context

CYTOKINETICS CEO Robert Blum filed a Form 4 selling 7,500 shares at $77.21 on 2026-05-27 under a 10b5-1 plan.

Expected impact

Likely limited near-term impact; any reaction would be sentiment-driven rather than a new fundamental catalyst.

Evidence & confidence

The filing is primary-source and time-stamped, but it is explicitly pre-arranged under Rule 10b5-1, which typically dampens interpretive value for traders.

Market effects

Sector

No direct sector read-through; this is company-specific insider activity.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Because the sale is under a pre-arranged 10b5-1 plan, it may reflect routine liquidity planning rather than bearish expectations.

Key entities

  • issuer
    CYTOKINETICS INC

    Company whose CEO insider sale is disclosed via SEC Form 4.

  • insider
    Blum Robert I

    President and CEO who sold 7,500 shares at $77.21 under a 10b5-1 plan.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

CYTK insider trading history →

Related articles

AUG 28
MedAI 9/10

Cytokinetics Posts First Full MYQORZO Quarter as Armistice Capital Adds to Its Position

Cytokinetics reported $25.3M in MYQORZO sales for Q2, with 700+ healthcare providers prescribing it. Armistice Capital increased its stake by 57% to 1.2M shares. The company plans to submit a supplemental drug application for non-obstructive HCM in Q4 2026. Total revenue fell to $28.6M from $66.8M YoY due to lower collaboration payments. Cytokinetics ended Q2 with $1.7B in cash and investments.

punchng.com2 min
AUG 28
$CYTKMedAI 8/10

Why Cytokinetics (CYTK) Stock Is Down Today

Cytokinetics (CYTK) shares fell 7.7% following the release of full Phase 3 ACACIA-HCM trial data for aficamten, which met primary endpoints but showed treatment interruptions and adverse events. The next milestone is a 2026 FDA filing. Investors may have already priced in positive topline results from May.

quiverquant.com2 min
AUG 28
$CYTKMedAI 8/10

CYTK Looks 64.3% Undervalued on GF Value™ Despite Profitability

Cytokinetics Inc (CYTK) saw its stock decline after detailed Phase 3 trial data for Myqorzo was released. The company plans to file an FDA application in Q4 2026. CYTK trades at a high P/S ratio of 136.11, with a GF Value™ suggesting it is 64.3% undervalued. The GF Score™ is 51/100, indicating moderate fundamentals with weak profitability and financial strength. Insiders have sold $43.7M in shares, while 8 gurus hold positions, with mixed activity.

gurufocus.com3 min
AUG 14
$CAPRMedAI 8/10

Capricor shares spike on CEO comments; Cytokinetics sues Bristol Myers

Capricor Therapeutics shares rose over 60% after CEO Linda Marbán said the FDA is willing to review an amended deramiocel submission for Duchenne muscular dystrophy, with an Aug. 22 decision deadline. Cytokinetics sued Bristol Myers Squibb over patents tied to Myqorzo. Valneva gained after EMA accepted a Pfizer vaccine application. Other updates covered funding, licensing, and drug availability.

finance.yahoo.com4 min
AUG 13
$CYTKMedAI 8/10

Cytokinetics (CYTK) Q2 2026 Earnings Call Transcript

Cytokinetics (CYTK) reported Q2 2026 revenue of $28.6M, down from $66.8M in 2025 due to fewer Bayer milestone payments, with MYQORZO net product revenue of $25.3M. Cash and investments were $1.7B after a May offering. Operating expense guidance was raised to $860M-$890M; net loss was $198.8M. MYQORZO new-to-brand share exceeded 40% in June.

fool.com10 min
AUG 6
$CYTKMedAI 8/10

CYTOKINETICS INC (CYTK): Results of Operations and Financial Condition

CYTOKINETICS INC (CYTK) filed an SEC Form 8-K — Results of Operations and Financial Condition. Cytokinetics Reports Second Quarter 2026 Financial Results and Provides Business Update MYQORZO ® (aficamten) Net Product Revenue of $25 Million Full Results from ACACIA-HCM to be Presented in Hot Line Session at ESC; Expect to Submit Supplemental NDA for Aficamten in Non-Obstruc

SEC EDGAR 8-K6 min